deltatrials
Recruiting PHASE3 INTERVENTIONAL 3-arm NCT06346392

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)

Sponsor: AstraZeneca

Conditions Gastric Cancer Gastroesophageal Junction Cancer
Interventions AZD0901 Apatinib Docetaxel Irinotecan Paclitaxel Ramucirumab+ paclitaxel TAS-102
Updated 19 times since 2024 Last updated: Mar 6, 2026 Started: Mar 4, 2024 Primary completion: May 14, 2026 Completion: Sep 14, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Gastric Cancer and Gastroesophageal Junction Cancer and is currently actively recruiting participants. AstraZeneca leads this study, which shows 19 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 6 months · monthly snapshot

Change History

19 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE3

  2. Feb 2026 — Mar 2026 [monthly]

    Recruiting PHASE3

  3. Jan 2026 — Feb 2026 [monthly]

    Recruiting PHASE3

  4. Dec 2025 — Jan 2026 [monthly]

    Recruiting PHASE3

  5. Nov 2025 — Dec 2025 [monthly]

    Recruiting PHASE3

▶ Show 14 earlier versions

  1. Sep 2025 — Nov 2025 [monthly]

    Recruiting PHASE3

  2. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE3

  3. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE3

  4. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE3

  5. May 2025 — Jun 2025 [monthly]

    Recruiting PHASE3

  6. Apr 2025 — May 2025 [monthly]

    Recruiting PHASE3

  7. Feb 2025 — Apr 2025 [monthly]

    Recruiting PHASE3

  8. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE3

  9. Nov 2024 — Jan 2025 [monthly]

    Recruiting PHASE3

  10. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE3

  11. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE3

  12. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  13. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  14. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Bangkok, Thailand , Barcelona, Spain , Barrie, Canada , Beijing, China , Bengaluru, India and 144 more locations